Allos Therapeutics to Report Second Quarter 2010 Financial Results on July 28, 2010
July 12 2010 - 9:00AM
Business Wire
Allos Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics, today announced that the
Company will report its financial results for the second quarter
ended June 30, 2010 on Wednesday, July 28, 2010 before the
financial markets open. Following the release of the financial
results, Allos management will provide a corporate update and
review of the second quarter 2010 results via audio webcast
conference call on Wednesday, July 28, 2010, at 8:30 a.m. Eastern
Time (ET).
To access the live audio webcast or the subsequent archived
recording, visit the “Investors - Presentations and Events” section
of the Company’s website at www.allos.com. Alternatively, callers
may participate in the conference call by dialing 1-866-225-8754
(domestic) or 480-629-9690 (international). Participants should
reference the Allos Therapeutics conference call. Webcast and
telephone replays of the conference call will be available
approximately two hours after the completion of the call through
August 11, 2010. To access the replay, callers should dial
1-800-406-7325 (domestic) or 303-590-3030 (international) and use
passcode 4329512#.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. Allos is currently focused on
the development and commercialization of FOLOTYN® (pralatrexate
injection), a folate analogue metabolic inhibitor. FOLOTYN is the
first and only drug approved in the U.S. for the treatment of
patients with relapsed or refractory peripheral T-cell lymphoma.
Allos is also developing FOLOTYN in other potential indications.
Allos retains exclusive worldwide rights to FOLOTYN for all
indications. Allos is headquartered in Westminster, CO. For
additional information, please visit www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties.
Additional information concerning these forward-looking statements
and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's
Quarterly Report on Form 10-Q for the quarter ended March 31, 2010
and in the Company's other periodic reports and filings with the
Securities and Exchange Commission. The Company cautions investors
not to place undue reliance on the forward-looking statements
contained in the presentation. All forward-looking statements are
based on information currently available to the Company on the date
thereof, and the Company undertakes no obligation to revise or
update these forward-looking statements to reflect events or
circumstances after the date of these presentations, except as
required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From May 2024 to Jun 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2023 to Jun 2024